Amgen

Amgen

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company founded in 1980 with headquarters in Thousand Oaks, California.

Amgen works in discovery, development and manufacturing of human therapeutics for treatment of illnesses in the areas of oncology, hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

Products

Amgen’s products include the following: Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine)and Aimovig.

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in Europe) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with Novartis as a drug to prevent migraines .

Clinical Trials

The following Amgen therapeutics are candidates in Phase III clinical trials: Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis.

The following Amgen therapeutics are candidates in Phase II clinical trials: BLINCYTO for diffuse Large B-Cell Lymphoma (DLBCL) and relapsed/refractory Philadelphia positive (R/R Ph+) and minimal residual disease of ALL; Erenumab for Chronic migraine; AMG 157 for asthma and atopic dermatitis; AMG 520 for Alzheimer's disease, and AMG 899 for dyslipidemia.

The following Amgen therapeutics are candidates in Phase I clinical trials: IMLYGIC for various cancer types; KYPROLIS for small-cell lung cancer; Oprozomib for multiple myeloma; AMG 176 for various cancer types; AMG 211 for various cancer types; AMG 224 for multiple myeloma, and AMG 301 for migraine. The Company's product candidates in Phase I also include AMG 330 for acute myeloid leukemia; AMG 420 for multiple myeloma; AMG 557 for systemic lupus erythematosus; AMG 570 for systemic lupus erythematosus; AMG 592 for inflammatory diseases; AMG 820 for various cancer types, and AMG 986 for heart failure.

Timeline

December 22, 2020
Amgen and Medicines Development for Global Health (MDGH) announces that the companies have entered into a license agreement for AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor being investigated for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.
November 23, 2020
Amgen announces it has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.

November 9, 2020
Amgen and AstraZeneca announce positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe asthma.

2019
Amgen acquires AMG 634 (formerly CC-11050) as part of its acquisition of Otezla® (apremilast) from Celgene.

Funded Companies

Company
Description
Industry
Website
Location
PTC Therapeutics

A biopharmaceutical company focused on discovery and development of small-molecule drugs to treat genetic and rare diseases

miRagen is a clinical stage biopharmaceutical company developing innovative microRNA-targeting therapies to improve human health.

DNA sequencing company specializing in rapid long-read sequencing through nanopores.

Gamida Cell is a biotechnology company developing cell therapies for treating cancer and hematologic diseases.

A biopharmaceutiical company discovering, developing and manufacturing therapeutics for the treatment of canccer

A biopharmaceutical company focused on the discovery and development of epigenetic medicines to treat cancer and other disease

A biotechnology company developing drugs for the treatment of metabolic diseases, cancer and inflammation

A biopharmaceutical company developing oral therapeutics for the treatment of mineral metabolism and metabolic disorders

A company developing technologies in protein-based therapeutics

A biotechnology company that develops therapeutic antibodies for treating infectious diseases and inflammation

A company that develops therapeutic oral medicines for the treatment of cancer and inflammatory diseases

SiteOne Therapeutics is a Bozeman, Montana-based developer of products for therapeutics and diagnostics.

A consulting and research services company for science companies

A biotechnology company developing peptides and antibodies for inflammation and autoimmunity

A biopharmaceutical company developing treatments for neuroendocrine, metabolic and immune disorders

A company designing bio-therapeutics for endocrine and other disorders

Opsona Therapeutics is a Dublin-based company.

A company developing cancer therapeutics

20 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Abid AZAM

Employee

Adam Hardin

Employee

Aditya Nag

Employee

aditya narula

Employee

Ahilaa Kamuthurai

Employee

AKASH ARYA

Employee

Alan Jamijian

Employee

Albert Hidayat

Employee

Alberto Chan

Employee

Alejandro Diaz

Employee

Alekhya Narni

Employee

Aleksander Malinowski

Employee

Alessandro Seveso

Employee

Alex Marzo

Employee

Alex Roman

Employee

Alex Shoshitaishvili

Employee

Alexander Julian Veach

Employee

Alfonso Kondo

Employee

Alfredo Zambonini

Employee

Alice Augustine

Employee

Alina Karimova

Employee

Alix Taffle

Employee

Allen Walker

Employee

Allison S

Employee

Alok Gandhi

Employee

Page 1 of 27
...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
January 14, 2021
FierceBiotech
NewAmsterdam Pharma has raised $196 million to fund late-phase trials of a cardiovascular disease drug discarded by Amgen. The series A will support the revitalization of obicetrapib, part of the once-hyped CETP class of molecules that was torpedoed by a series of clinical setbacks.
Ben Adams
January 13, 2021
FierceBiotech
Amgen has penned a deal worth $240 million-plus with biotech Evoq Therapeutics as it looks to the future for autoimmune research.
EVOQ Therapeutics
January 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for...
Amgen
January 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of a new seven-year environmental sustainability plan, which includes a commitment to achieve...
Amgen
January 6, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 39th Annual J.P. Morgan Healthcare Conference at 11:50 a.m. PT on Monday, Jan. 11, 2021. Robert A....
Nektar Therapeutics
January 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development...
Amirah Al Idrus
January 4, 2021
FierceBiotech
On the heels of its first approval, Myovant Sciences is tapping a new CEO to take that drug to market while stoking its R&D engine to find its successors. Dave Marek takes over from Lynn Seely, M.D., the company's chief since June 2016.
Scopus BioPharma Inc.
December 29, 2020
www.prnewswire.com:443
/PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a...
Amgen
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ: AMGN) gab heute die Einreichung eines Zulassungsantrags (MAA) bei der Europäischen Arzneimittelagentur (EMA) für Sotorasib,...
Amgen
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ: AMGN) a annoncé aujourd'hui la soumission d'une demande d'autorisation de mise sur le marché (AAM) à l'Agence européenne des...
Amgen
December 23, 2020
www.prnewswire.com:443
/PRNewswire/-- Amgen (NASDAQ: AMGN) ha reso noto di aver presentato una richiesta di autorizzazione all'immissione in commercio (MAA) all'Agenzia europea per i...
Amgen
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ: AMGN) anunció hoy la presentación de una Solicitud de Autorización de Comercialización (MAA) a la Agencia Europea del...
Amgen
December 22, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the...
Nick Paul
December 22, 2020
FierceBiotech
A phase 3 clinical trial of Amgen and AstraZeneca's asthma candidate tezepelumab has missed its primary endpoint. The failure comes weeks after tezepelumab hit the endpoint in another phase 3, leaving the partners with a mixed data set they still plan to use to seek regulatory approvals next year.
Amgen
December 22, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction...
Amgen
December 17, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that Octagon Therapeutics and Seranova Bio have each won an Amgen Golden Ticket to...
Phil Taylor
December 17, 2020
FierceBiotech
Amgen has maintained its lead in the race to bring a KRAS-targeting medicine to market after filing for approval of sotorasib in non-small cell lung cancer in the U.S.
Amgen
December 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the first quarter of 2021. The dividend...
Amgen
December 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sotorasib, an...
American College of Cardiology
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- The American College of Cardiology, in collaboration with Amgen and Veradigm, today announced a new national study to transform care for acute...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.